CN113473982A - 使用多西他赛和cyp3a抑制剂组合治疗实体瘤 - Google Patents

使用多西他赛和cyp3a抑制剂组合治疗实体瘤 Download PDF

Info

Publication number
CN113473982A
CN113473982A CN201980090621.4A CN201980090621A CN113473982A CN 113473982 A CN113473982 A CN 113473982A CN 201980090621 A CN201980090621 A CN 201980090621A CN 113473982 A CN113473982 A CN 113473982A
Authority
CN
China
Prior art keywords
docetaxel
cyp3a
dose
cancer
cyp3a inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980090621.4A
Other languages
English (en)
Chinese (zh)
Inventor
雅克布·昂德里克·拜占恩
乔纳斯·亨里克斯·马提亚·舍伦斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Modra Pharmaceuticals BV
Original Assignee
Modra Pharmaceuticals BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modra Pharmaceuticals BV filed Critical Modra Pharmaceuticals BV
Publication of CN113473982A publication Critical patent/CN113473982A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980090621.4A 2018-12-21 2019-12-18 使用多西他赛和cyp3a抑制剂组合治疗实体瘤 Pending CN113473982A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18215488.0 2018-12-21
EP18215488 2018-12-21
PCT/EP2019/086125 WO2020127607A1 (en) 2018-12-21 2019-12-18 Combination treatment for solid tumors using docetaxel and a cyp3a inhibitor

Publications (1)

Publication Number Publication Date
CN113473982A true CN113473982A (zh) 2021-10-01

Family

ID=64901398

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980090621.4A Pending CN113473982A (zh) 2018-12-21 2019-12-18 使用多西他赛和cyp3a抑制剂组合治疗实体瘤

Country Status (13)

Country Link
US (1) US20220071944A1 (enExample)
EP (1) EP3897611A1 (enExample)
JP (3) JP2022514960A (enExample)
KR (1) KR20220004011A (enExample)
CN (1) CN113473982A (enExample)
AU (2) AU2019410062A1 (enExample)
BR (1) BR112021012266A2 (enExample)
CA (1) CA3124319C (enExample)
CL (1) CL2021001635A1 (enExample)
IL (1) IL284225A (enExample)
MX (1) MX2021007480A (enExample)
PE (1) PE20220129A1 (enExample)
WO (1) WO2020127607A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113543781A (zh) * 2018-12-21 2021-10-22 莫德拉药物股份有限责任公司 通过控制峰值血浆水平使用多西他赛的癌症治疗
CN116270617A (zh) * 2023-03-29 2023-06-23 济宁医学院附属医院 Arp2/3复合物抑制剂CK-666和多西他赛组合用于癌症治疗

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202201935D0 (en) 2022-02-14 2022-03-30 Modra Pharmaceuticals B V Methods and compositions for treating cancer in taxane-resistant patients

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009027644A2 (en) * 2007-08-24 2009-03-05 Stichting Het Nederlands Kanker Instituut Composition
CN113543781A (zh) * 2018-12-21 2021-10-22 莫德拉药物股份有限责任公司 通过控制峰值血浆水平使用多西他赛的癌症治疗

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0716591D0 (en) * 2007-08-24 2007-10-03 Vereniging Het Nl Kanker I Composition
US9089544B2 (en) * 2007-08-24 2015-07-28 Slotervaart Participaties Bv Composition
EP2328555A2 (en) 2008-08-22 2011-06-08 Slotervaart Participaties BV Compositions for the treatment of neoplastic diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009027644A2 (en) * 2007-08-24 2009-03-05 Stichting Het Nederlands Kanker Instituut Composition
CN113543781A (zh) * 2018-12-21 2021-10-22 莫德拉药物股份有限责任公司 通过控制峰值血浆水平使用多西他赛的癌症治疗

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DE WEGER V A等: "A dose-escalation study of bi-daily once weekly oral docetaxel either as ModraDoc001 or ModraDoc006 combined with ritonavir", 《EUROPEAN JOURNAL OF CANCER》, 12 October 2017 (2017-10-12), pages 217 - 225 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113543781A (zh) * 2018-12-21 2021-10-22 莫德拉药物股份有限责任公司 通过控制峰值血浆水平使用多西他赛的癌症治疗
CN116270617A (zh) * 2023-03-29 2023-06-23 济宁医学院附属医院 Arp2/3复合物抑制剂CK-666和多西他赛组合用于癌症治疗
CN116270617B (zh) * 2023-03-29 2024-01-26 济宁医学院附属医院 Arp2/3复合物抑制剂CK-666和多西他赛组合用于癌症治疗的制药用途

Also Published As

Publication number Publication date
AU2023204693A1 (en) 2023-08-10
CA3124319A1 (en) 2020-06-25
CA3124319C (en) 2023-07-04
IL284225A (en) 2021-08-31
WO2020127607A1 (en) 2020-06-25
JP2025094186A (ja) 2025-06-24
BR112021012266A2 (pt) 2021-08-31
EP3897611A1 (en) 2021-10-27
JP2023102786A (ja) 2023-07-25
PE20220129A1 (es) 2022-01-27
US20220071944A1 (en) 2022-03-10
CL2021001635A1 (es) 2022-04-22
KR20220004011A (ko) 2022-01-11
MX2021007480A (es) 2021-10-13
AU2019410062A1 (en) 2021-08-12
JP2022514960A (ja) 2022-02-16

Similar Documents

Publication Publication Date Title
US20250312305A1 (en) Cancer Treatment Using Docetaxel by Controlling Peak Plasma Levels
AU2023204693A1 (en) Combination treatment for solid tumors using docetaxel and a cyp3a inhibitor
US20240091194A1 (en) 6-(2,4-Dichlorophenyl)-5-[4-[(3S)-1-(3-Fluoropropyl)Pyrrolidin-3-Yl]Oxyphenyl]-8,9-Dihydro-7H-Benzo[7]Annulene-2-Carboxylic Acid For Use In Metastatic Or Advanced Breast Cancer Patients
CA3253688A1 (en) TREATMENT METHODS FOR SMALL CELL LUNG CANCER
KR20080081249A (ko) 17-ａａｇ 또는 17-ａｇ, 또는 이 중 어느 하나의 전구약물과 ｈｅｒ２ 억제제의 조합을 사용하여 유방암을치료하는 방법
CN114177299A (zh) 包含ezh2抑制剂和scd1抑制剂的抗肿瘤药物组合物及其用途
TW202302084A (zh) 以安森司坦和帕博西尼治療乳癌
EP4385507A1 (en) Combination treatment for solid tumors using cabazitaxel and a cyp3a inhibitor
HK40111479A (en) Combination treatment for solid tumors using cabazitaxel and a cyp3a inhibitor
CN118946350A (zh) 用于治疗紫杉烷耐药性患者的癌症的方法和组合物
CN101528705A (zh) 17-aag或17-ag或两者之一的前药与her2抑制剂联用治疗乳腺癌的方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination